Get the Stockscreener App
9.64
0.52%
0.05
After Hours:
9.40
-0.24
-2.49%
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus Therapeutics (NASDAQ:FOLD) shareholders have endured a 26% loss from investing in the stock a year ago - Simply Wall St
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Inspire Investing LLC - MarketBeat
Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025 - MSN
Leerink Partnrs Issues Optimistic Estimate for FOLD Earnings - MarketBeat
Research Analysts Set Expectations for FOLD Q2 Earnings - MarketBeat
Assenagon Asset Management S.A. Has $4.49 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
Jefferies Initiates Coverage of Amicus Therapeutics (FOLD) with Buy Recommendation - MSN
Cantor Fitzgerald Reaffirms Overweight Rating for Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Enzyme Replacement Therapy Market Deep Research Report with - openPR
When (FOLD) Moves Investors should Listen - Stock Traders Daily
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.88 - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook - MSN
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpStill a Buy? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Earns Hold Rating from Needham & Company LLC - MarketBeat
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts - Benzinga
Shareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past week - Yahoo Finance
Fabry Disease Treatment Market Top Companies StudySanofi SA, - openPR
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook - GlobeNewswire
Amicus Therapeutics Reports Stellar 32% Revenue Growth to $528.5M, Eyes $1B Sales Target - StockTitan
Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Canada
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year LowShould You Sell? - MarketBeat
Amicus Therapeutics stock hits 52-week low at $9.01 - Investing.com
Principal Financial Group Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Principal Financial Group Inc. - MarketBeat
How the (FOLD) price action is used to our Advantage - Stock Traders Daily
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Amicus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
JPMorgan Chase & Co. Sells 1,984,751 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Trimmed by JPMorgan Chase & Co. - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Update - MarketBeat
Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues - Simply Wall St
Amicus Therapeutics: Cheap Heading Into 2025 (NASDAQ:FOLD) - Seeking Alpha
Stifel Financial Corp Sells 21,615 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Geode Capital Management LLC Acquires 80,926 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at StockNews.com - MarketBeat
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):